



NDA 021881/S-017

SUPPLEMENT APPROVAL

Salix Pharmaceuticals, Inc.
Attention: Mary Harrell
Senior Director, Global Regulatory Affairs
Valeant Pharmaceuticals North America LLC
400 Somerset Corporate Boulevard
Bridgewater, NJ 08807

Dear Ms. Harrell:

Please refer to your Supplemental New Drug Application (sNDA) dated June 29, 2018, received June 29, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for MoviPrep (polyethylene glycol 3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution).

This Prior Approval supplemental new drug application provides for updates to the Prescribing Information to reflect the Pregnancy and Lactation Labeling Rule (PLLR) format.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text with minor edits to update the revision date at the end of: Highlights in the Prescribing Information, the Medication Guide and the Instructions for Use.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Andrew Kelleher, Ph.D., Regulatory Project Manager, at (301)796-9330 or e-mail andrew.kelleher@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Jessica J. Lee, M.D., M.M.Sc.
Associate Director
Division of Gastroenterology and Inborn Errors
Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

ENCLOSURE(S):

Content of Labeling
Prescribing Information
Medication Guide
Instructions for Use

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JESSICA J LEE
12/07/2018